» Articles » PMID: 36531960

Extracellular Vesicle DNA from Human Melanoma Tissues Contains Cancer-specific Mutations

Overview
Specialty Cell Biology
Date 2022 Dec 19
PMID 36531960
Authors
Affiliations
Soon will be listed here.
Abstract

Liquid biopsies are promising tools for early diagnosis and residual disease monitoring in patients with cancer, and circulating tumor DNA isolated from plasma has been extensively studied as it has been shown to contain tumor-specific mutations. Extracellular vesicles (EVs) present in tumor tissues carry tumor-derived molecules such as proteins and nucleic acids, and thus EVs can potentially represent a source of cancer-specific DNA. Here we identified the presence of tumor-specific DNA mutations in EVs isolated from six human melanoma metastatic tissues and compared the results with tumor tissue DNA and plasma DNA. Tumor tissue EVs were isolated using enzymatic treatment followed by ultracentrifugation and iodixanol density cushion isolation. A panel of 34 melanoma-related genes was investigated using ultra-sensitive sequencing (SiMSen-seq). We detected mutations in six genes in the EVs (, , , , , and ), and at least one mutation was detected in all melanoma EV samples. Interestingly, the mutant allele frequency was higher in DNA isolated from tumor-derived EVs compared to total DNA extracted directly from plasma DNA, supporting the potential role of tumor EVs as future biomarkers in melanoma.

Citing Articles

Stoichiometric constraints for detection of EV-borne biomarkers in blood.

Zarovni N, Mladenovic D, Brambilla D, Panico F, Chiari M J Extracell Vesicles. 2025; 14(2):e70034.

PMID: 39901737 PMC: 11791308. DOI: 10.1002/jev2.70034.


Prospects and Current Challenges of Extracellular Vesicle-Based Biomarkers in Cancer.

Lawrence S, Shah K Biology (Basel). 2024; 13(9).

PMID: 39336121 PMC: 11428408. DOI: 10.3390/biology13090694.


Blood-Derived Extracellular Vesicles as a Promising Liquid Biopsy Diagnostic Tool for Early Cancer Detection.

He D, Cui B, Lv H, Lu S, Zhu Y, Cheng Y Biomolecules. 2024; 14(7).

PMID: 39062561 PMC: 11275243. DOI: 10.3390/biom14070847.


Prospects and challenges of tissue-derived extracellular vesicles.

Lee J, Ray R, Scott T Mol Ther. 2024; 32(9):2950-2978.

PMID: 38910325 PMC: 11403234. DOI: 10.1016/j.ymthe.2024.06.025.


Research advances of tissue-derived extracellular vesicles in cancers.

Li W, Zhu J, Li J, Jiang Y, Sun J, Xu Y J Cancer Res Clin Oncol. 2024; 150(4):184.

PMID: 38598014 PMC: 11006789. DOI: 10.1007/s00432-023-05596-z.

References
1.
Cianciaruso C, Beltraminelli T, Duval F, Nassiri S, Hamelin R, Mozes A . Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. Cell Rep. 2019; 27(10):3062-3080.e11. PMC: 6581796. DOI: 10.1016/j.celrep.2019.05.008. View

2.
Lim S, Lee J, Diefenbach R, Kefford R, Rizos H . Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018; 17(1):8. PMC: 5772714. DOI: 10.1186/s12943-018-0757-5. View

3.
Xavier C, Caires H, Barbosa M, Bergantim R, Guimaraes J, Vasconcelos M . The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance. Cells. 2020; 9(5). PMC: 7290603. DOI: 10.3390/cells9051141. View

4.
Hodi F, Hwu W, Kefford R, Weber J, Daud A, Hamid O . Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016; 34(13):1510-7. PMC: 5070547. DOI: 10.1200/JCO.2015.64.0391. View

5.
Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudie H, Tanga V . Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018; 9(90):36238-36249. PMC: 6281416. DOI: 10.18632/oncotarget.26343. View